DATATRAK Releases New Version of uIRT

DATATRAK Releases New Version of uIRT
Empowering Clients with Control of Randomization and Inventory in the Cloud

CLEVELAND, Jan.18, 2012 /PRNewswire via COMTEX/ -- DATATRAK International, Inc. (otcqx:DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced a completely new product design for their randomization and clinical supplies management product, uIRT. As a unified product within the DATATRAK ONE(TM) suite, the new release of uIRT positions DATATRAK as the most advanced unified Randomization and Clinical Supplies Management system in the marketplace today.

"DATATRAK has been supporting clinical trial randomizations and drug inventory management since 2005," stated DATATRAK CTO Chris Wilke. "With this new release, we've made huge strides in the technologies available to the marketplace today. We listened to our clients and have now turned over the control of managing trial randomizations to Sponsors and CROs."

Clients can configure and maintain randomization and clinical supply allocation throughout the life of the clinical trial without DATATRAK assistance. With this new release, users will experience the following:

Increased performance when generating randomization schedules, importing strata and populating or importing inventory schedules.

Robust Manager functionality allowing users to view, filter, update and export information on drug containers, drug assignments, shipments and randomization schedules.

Standard reports and system-wide exports available 24/7 in real-time to effectively manage time sensitive randomization and inventory needs.

About DATATRAK

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services(TM) group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE(TM) software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net .

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending September 30, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

 

 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.